Search

Your search keyword '"Burtin, Pascal"' showing total 173 results
Start Over Author "Burtin, Pascal"
173 results on '"Burtin, Pascal"'

4. Systematic Resection of the Visible Scar After Incomplete Endoscopic Resection of Rectal Neuroendocrine Tumors

Author

Cheminel, Loïc, primary, Lupu, Alexandru, additional, Wallenhorst, Timothée, additional, Lepilliez, Vincent, additional, Leblanc, Sarah, additional, Albouys, Jérémie, additional, Abou Ali, Einas, additional, Barret, Maximilien, additional, Lorenzo, Diane, additional, De Mestier, Louis, additional, Burtin, Pascal, additional, Girot, Paul, additional, Le Baleur, Yann, additional, Gerard, Romain, additional, Yzet, Clara, additional, Tchirikhtchian, Karl, additional, Degand, Thibault, additional, Culetto, Adrian, additional, Lemmers, Arnaud, additional, Schaefer, Marion, additional, Chevaux, Jean-Baptiste, additional, Zhong, Peng, additional, Hervieu, Valérie, additional, Subtil, Fabien, additional, Rivory, Jérôme, additional, Fine, Caroline, additional, Jacques, Jérémie, additional, Walter, Thomas, additional, and Pioche, Mathieu, additional

Published
2023
Full Text
View/download PDF

5. Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations

Author

Tarabay, Anthony, primary, Boileve, Alice, additional, Smolenschi, Cristina, additional, Antoun, Leony, additional, Valery, Marine, additional, Fuerea, Alina, additional, Perret, Audrey, additional, Burtin, Pascal, additional, Cosconea, Simona, additional, Belkhodja, Hichem, additional, Malka, David, additional, Boige, Valérie, additional, Hollebecque, Antoine, additional, and Ducreux, Michel, additional

Published
2023
Full Text
View/download PDF

7. Systematic Resection of the Visible Scar After Incomplete Endoscopic Resection of Rectal Neuroendocrine Tumors.

Author

Cheminel, Loïc, Lupu, Alexandru, Wallenhorst, Timothée, Lepilliez, Vincent, Leblanc, Sarah, Albouys, Jérémie, Ali, Einas Abou, Barret, Maximilien, Lorenzo, Diane, De Mestier, Louis, Burtin, Pascal, Girot, Paul, Yann Le Baleur, Gerard, Romain, Yzet, Clara, Tchirikhtchian, Karl, Degand, Thibault, Culetto, Adrian, Lemmers, Arnaud, and Schaefer, Marion

Published
2024
Full Text
View/download PDF

9. Molecular precision medicine in pancreatic cancer: A single-center experience.

Author

Tarabay, Anthony, primary, Hollebecque, Antoine, additional, Smolenschi, Cristina, additional, Antoun, Leony, additional, Klotz, Caroline, additional, Fuerea, Alina, additional, Perret, Audrey, additional, Gouriou, Claire, additional, Burtin, Pascal, additional, Belkhodja, Hichem, additional, Boige, Valérie, additional, Malka, David, additional, and Ducreux, Michel, additional

Published
2022
Full Text
View/download PDF

13. Pulse-dose-rate interstitial brachytherapy in anal squamous cell carcinoma: clinical outcomes and patients’ health quality perception

Author

Bourdais, Rémi, primary, Achkar, Samir, additional, Espenel, Sophie, additional, Bockel, Sophie, additional, Chauffert-Yvart, Laetitia, additional, Ravet de Mellis, Florence, additional, Ta, Minh-Hanh, additional, Boukhelif, Wassila, additional, Durand-Labrunie, Jérôme, additional, Burtin, Pascal, additional, Haie-Meder, Christine, additional, Deutsch, Eric, additional, and Chargari, Cyrus, additional

Published
2021
Full Text
View/download PDF

14. Long-Term Results after Surgical Resection of Peritoneal Metastasis from Neuroendocrine Tumors

Author

Benhaim, Léonor, primary, Faron, Matthieu, additional, Hadoux, Julien, additional, Gelli, Maximiliano, additional, Sourrouille, Isabelle, additional, Burtin, Pascal, additional, Honoré, Charles, additional, Malka, David, additional, Leboulleux, Sophie, additional, Ducreux, Michel, additional, Scoazec, Jean-Yves, additional, Goere, Diane, additional, and Baudin, Eric, additional

Published
2020
Full Text
View/download PDF

15. Adenoma detection by Endocuff-assisted versus standard colonoscopy in routine practice: a cluster-randomised crossover trial

Author

Karsenti, David, primary, Tharsis, Gaelle, additional, Perrot, Bastien, additional, Cattan, Philippe, additional, Tordjman, Gilles, additional, Venezia, Franck, additional, Zrihen, Elie, additional, Gillot, Dominique, additional, Gillet, Agnes, additional, Hagege, Charles, additional, Samama, Joelle, additional, Etienney, Isabelle, additional, Lab, Jean-Philippe, additional, Guigui, Bernard, additional, Zago, Jacqueline, additional, Benkessou, Bouchra, additional, Burtin, Pascal, additional, and Cavicchi, Maryan, additional

Published
2020
Full Text
View/download PDF

16. Role of precision medicine for patients with advanced biliary tract cancers.

Author

Hollebecque, Antoine, primary, Nabi, Oumrou, additional, Ducreux, Michel, additional, Boige, Valerie, additional, Scoazec, Jean-Yves, additional, Rouleau, Etienne, additional, Boileve, Alice, additional, Smolenschi, Cristina, additional, Verlingue, Loic, additional, Matias, Margarida, additional, Burtin, Pascal, additional, Prieux-Klotz, Caroline, additional, Massard, Christophe, additional, and Malka, David, additional

Published
2020
Full Text
View/download PDF

19. Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity?

Author

Hadoux, Julien, primary, Blanchard, Pierre, additional, Scoazec, Jean-Yves, additional, Burtin, Pascal, additional, Planchard, David, additional, Malka, David, additional, Berdelou, Amandine, additional, Boige, Valérie, additional, Duvillard, Pierre, additional, Leboulleux, Sophie, additional, Faron, Matthieu, additional, Tselikas, Lambros, additional, Deutsch, Eric, additional, Ducreux, Michel, additional, and Baudin, Eric, additional

Published
2019
Full Text
View/download PDF

20. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer

Author

Calais Gilles, Burtin Pascal, Carrie Christian, Salemkour Augustin, Vendrely Véronique, Chevelle Christian, Vié Brigitte, Martin Laurent, Leduc Bernard, Cellier Patrice, Campion Loïc, Boisdron-Celle Michèle, Morel Alain, Berger Virginie, and Gamelin Erick

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Considerable variation in intravenous 5-fluorouracil (5-FU) metabolism can occur due to the wide range of dihydropyrimidine dehydrogenase (DPD) enzyme activity, which can affect both tolerability and efficacy. The oral fluoropyrimidine tegafur-uracil (UFT) is an effective, well-tolerated and convenient alternative to intravenous 5-FU. We undertook this study in patients with locally advanced rectal cancer to evaluate the efficacy and tolerability of UFT with leucovorin (LV) and preoperative radiotherapy and to evaluate the utility and limitations of multicenter staging using pre- and post-chemoradiotherapy ultrasound. We also performed a validated pretherapy assessment of DPD activity and assessed its potential influence on the tolerability of UFT treatment. Methods This phase II study assessed preoperative UFT with LV and radiotherapy in 85 patients with locally advanced T3 rectal cancer. Patients with potentially resectable tumors received UFT (300 mg/m/2/day), LV (75 mg/day), and pelvic radiotherapy (1.8 Gy/day, 45 Gy total) 5 days/week for 5 weeks then surgery 4-6 weeks later. The primary endpoints included tumor downstaging and the pathologic complete response (pCR) rate. Results Most adverse events were mild to moderate in nature. Preoperative grade 3/4 adverse events included diarrhea (n = 18, 21%) and nausea/vomiting (n = 5, 6%). Two patients heterozygous for dihydropyrimidine dehydrogenase gene (DPYD) experienced early grade 4 neutropenia (variant IVS14+1G > A) and diarrhea (variant 2846A > T). Pretreatment ultrasound TNM staging was compared with postchemoradiotherapy pathology TN staging and a significant shift towards earlier TNM stages was observed (p < 0.001). The overall downstaging rate was 42% for primary tumors and 44% for lymph nodes. The pCR rate was 8%. The sensitivity and specificity of ultrasound for staging was poor. Anal sphincter function was preserved in 55 patients (65%). Overall and recurrence-free survival at 3 years was 86.1% and 66.7%, respectively. Adjuvant chemotherapy was administered to 36 node-positive patients (mean duration 118 days). Conclusion Preoperative chemoradiotherapy using UFT with LV plus radiotherapy was well tolerated and effective and represents a convenient alternative to 5-FU-based chemoradiotherapy for the treatment of resectable rectal cancer. Pretreatment detection of DPD deficiency should be performed to avoid severe adverse events.

Published
2011
Full Text
View/download PDF

21. Long-Term Results after Surgical Resection of Peritoneal Metastasis from Neuroendocrine Tumors.

Author

Benhaim, Léonor, Faron, Matthieu, Hadoux, Julien, Gelli, Maximiliano, Sourrouille, Isabelle, Burtin, Pascal, Honoré, Charles, Malka, David, Leboulleux, Sophie, Ducreux, Michel, Scoazec, Jean-Yves, Goere, Diane, and Baudin, Eric

Subjects
NEUROENDOCRINE tumors, SURGICAL excision, OVERALL survival, LIVER metastasis, SMALL intestine, LIVER surgery
Abstract

Introduction: Peritoneal metastases from neuroendocrine tumors are associated with a bad prognosis. The objective of our study was to evaluate whether surgical resection could lead to prolonged survival in selected patients. This survival was compared to that of patients operated for liver metastasis. Methods: From our prospectively maintained database we included 88 patients who underwent the complete resection of peritoneal and/or liver metastasis between January 1995 and December 2016 in Gustave-Roussy. Three resection groups were compared: peritoneal metastasis alone, liver metastasis alone, and the combined resection of liver and peritoneal metastases. Results: The median peritoneal cancer index was 10 in the peritoneal group and 11 in the peritoneal + liver group. The 5-year overall survival was 81% (60–100) in the peritoneal group compared to 78% (65.2–92.8) in the liver group, and 72% (58.7–89.7) in the peritoneal + liver group (p = 0.71). The 3-year disease-free survival reached 26.9% (16.1–45.1) in the liver group, 12.5% (2.3–68.2) in the peritoneal group, and 32.4% (19.9–52.6) in the combined liver + peritoneal group (p = 0.45). In the univariate analysis, the prognosis factors for a longer survival were: small bowel primary tumor origin, low preoperative chromogranin A level, and tumor grade ≤1. Conclusion: Despite a high recurrence rate, long-term overall survival can be achieved after the resection of peritoneal metastasis in selected patients. This survival is comparable to that of patients operated for liver metastasis only. Surgery should stand as a standard treatment for peritoneal metastases in patients with resectable disease. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

25. Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity?

Author

Hadoux, Julien, Blanchard, Pierre, Scoazec, Jean-Yves, Burtin, Pascal, Planchard, David, Malka, David, Berdelou, Amandine, Boige, Valérie, Duvillard, Pierre, Leboulleux, Sophie, Faron, Matthieu, Tselikas, Lambros, Deutsch, Eric, Ducreux, Michel, and Baudin, Eric

Subjects
ENTEROCOLITIS, SMALL cell lung cancer, SECONDARY primary cancer, CANCER survivors, CANCER treatment, CARCINOMA, ALIMENTARY canal
Abstract

Background: Cancer survivors have a 14% increased risk of developing a malignancy compared with the general population. Second radiation-induced malignancies with different histologies have been described in different organs. Based on individual observations, we hypothesized that neuroendocrine carcinoma (NEC) could arise in irradiated organs. Methods: In a retrospective analysis of Gustave Roussy database of NEC patients (small cell lung cancer excluded) diagnosed as a second cancer, we looked for the frequency of grade 3 NEC that arose in patients who had received previous radiation therapy for a first cancer. Radiation therapy for the first cancer, dose, location of radiation therapy, pathological characteristics, overall survival, and response to treatment of secondary NEC were analyzed. Results: From January 1995 to December 2017, 847 cases of NEC were seen at Gustave Roussy. Among them, 95 (11.2%) patients had a history of previous malignancy of which 36 (4%) had been treated with radiation therapy. Out of these 36 patients, 12 (1.4% of all NEC patients) developed a NEC within the previous irradiated organ (median dose of 50 Gy, range 36–67.5). Most frequent first cancers were breast cancer (n = 4) and Hodgkin lymphoma (n = 3). NEC arose within a median time of 21.7 years (range 5.1–36.4) from radiation in the thorax (n = 5), digestive tract (n = 3), and other sites. Five large cell NEC, 3 small cell NEC, 1 mixed neuroendocrine neoplasm and 3 not otherwise specified NEC were diagnosed. Ten patients had stage IV disease at diagnosis; median overall survival was 37.8 months (95% CI [17.6 to NA]). Three patients (25%) achieved complete response with multimodal treatment. Conclusions: NEC can arise from previously irradiated organs and may have a better outcome in this setting. Other risk factors should be investigated to explain the high rate of previous cancer in this population of neuroendocrine neoplasm. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

26. Adenoma detection by Endocuff-assisted versus standard colonoscopy in routine practice: a clusterrandomised crossover trial.

Author

Karsenti, David, Tharsis, Gaelle, Perrot, Bastien, Cattan, Philippe, Tordjman, Gilles, Venezia, Franck, Zrihen, Elie, Gillot, Dominique, Gillet, Agnes, Hagege, Charles, Samama, Joelle, Etienney, Isabelle, Lab, Jean-Philippe, Guigui, Bernard, Zago, Jacqueline, Benkessou, Bouchra, Burtin, Pascal, and Cavicchi, Maryan

Subjects
FECAL occult blood tests, ADENOMA, CROSSOVER trials, COLON polyps, COLONOSCOPY, ADENOMATOUS polyps, SURGICAL clinics, RANDOMIZED controlled trials
Published
2020
Full Text
View/download PDF

27. Mo1661 ADENOMA AND ADVANCED NEOPLASIA DETECTION RATES INCREASE FROM 45 YEAR OF AGE: RESULTS OF A MONOCENTRIC ONE-YEAR OBSERVATIONAL COHORT STUDY ON 6027 COLONOSCOPIES

Author

Karsenti, David, primary, Tharsis, Gaelle, additional, Burtin, Pascal C., additional, Venezia, Franck, additional, Tordjman, Gilles, additional, Gillet, Agnes, additional, Samama, Joelle, additional, Nahon-Uzan, Karine, additional, Cattan, Philippe, additional, and Cavicchi, Maryan, additional

Published
2018
Full Text
View/download PDF

30. Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Author

Adenis, Antoine, primary, de la Fouchardiere, Christelle, additional, Paule, Bernard, additional, Burtin, Pascal, additional, Tougeron, David, additional, Wallet, Jennifer, additional, Dourthe, Louis-Marie, additional, Etienne, Pierre-Luc, additional, Mineur, Laurent, additional, Clisant, Stéphanie, additional, Phelip, Jean-Marc, additional, Kramar, Andrew, additional, and Andre, Thierry, additional

Published
2016
Full Text
View/download PDF

31. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Author

Adenis, Antoine, primary, de la Fouchardiere, Christelle, additional, Paule, Bernard, additional, Burtin, Pascal, additional, Tougeron, David, additional, Wallet, Jennifer, additional, Dourthe, Louis-Marie, additional, Etienne, Pierre-Luc, additional, Mineur, Laurent, additional, Clisant, Stéphanie, additional, Phelip, Jean-Marc, additional, Kramar, Andrew, additional, and Andre, Thierry, additional

Published
2016
Full Text
View/download PDF

32. Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study

Author

Berdelou, Amandine, primary, Boige, Valérie, additional, Arfi-Rouche, Julia, additional, Malka, David, additional, Ederhy, Stéphane, additional, Izzedine, Hassan, additional, Leboulleux, Sophie, additional, Chougnet, Cécile N., additional, Burtin, Pascal, additional, De Baere, Thierry, additional, Laplanche, Agnès, additional, Elias, Dominique, additional, Schlumberger, Martin, additional, Scoazec, Jean-Yves, additional, Ducreux, Michel, additional, and Baudin, Eric, additional

Published
2016
Full Text
View/download PDF

33. Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study.

Author

Berdelou, amandine, Boige, Valérie, arfi-Rouche, Julia, Malka, David, Ederhy, Stéphane, Izzedine, Hassan, Leboulleux, Sophie, Chougnet, Cécile N., Burtin, Pascal, De Baere, Thierry, Laplanche, agnès, Elias, Dominique, Schlumberger, Martin, Scoazec, Jean-Yves, Ducreux, Michel, and Baudin, Eric

Subjects
NEUROENDOCRINE tumors, THERAPEUTICS, SURVIVAL analysis (Biometry), TUMOR treatment
Abstract

Background: At least nine therapeutic options are recommended or approved for pancreatic neuroendocrine tumour (pNET). The primary endpoint of this study was to determine the number of therapeutic lines given before death. Secondary endpoints were to determine toxic events as a function of number of therapeutic lines and of time. Methods: Patients with pNET treated between 1998 and 2010 at our centre were characterised. All therapeutic lines were recorded as well as tumour- or toxic-related deaths. Persistent treatment-related toxicity (PTRT) was defined as: chronic kidney disease, anaemia, thrombocytopenia, neutropenia, severe liver failure, cardiac failure and recurrent sepsis, precluding at least one other therapeutic option or second cancers. Results: Ninety-two patients were analysed. The median follow-up was 7 years. The 1-, 2- and 5-year overall survival rates were 90, 81 and 51%, respectively. After 3 and 5 therapeutic lines, 23 and 50% of patients had died, respectively. After 3 and 5 lines, the frequency of toxic events was 8 and 24%, respectively. Overall, 17 toxic events were observed including 6 treatment-related deaths and 11 PTRT. After 1, 2 and 5 years of treatment, the frequency of toxic events was 6, 9 and 16%, respectively. Conclusion: Tumour- and toxic-related deaths as well as PTRT may preclude access to all therapeutic options in patients with pNET. Optimised risk benefit sequence should be investigated. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

34. Randomized Controlled Trial Comparing Outcomes of Video Capsule Endoscopy with Push Enteroscopy in Obscure Gastrointestinal Bleeding

Author

Segarajasingam, Dev S, primary, Hanley, Stephen C, additional, Barkun, Alan N, additional, Waschke, Kevin A, additional, Burtin, Pascal, additional, Parent, Josée, additional, Mayrand, Serge, additional, Fallone, Carlo A, additional, Jobin, Gilles, additional, Seidman, Ernest G, additional, and Martel, Myriam, additional

Published
2015
Full Text
View/download PDF

35. Axitinib in refractory colorectal metastatic cancer: A phase II study of increasing doses with dynamic contrast-enhanced ultrasonography monitory of the response.

Author

Ducreux, Michel, primary, Boige, Valerie, additional, Faivre, Laura, additional, Malka, David, additional, Burtin, Pascal, additional, Hollebecque, Antoine, additional, Villing, Anne-Laure, additional, Koscielny, Serge, additional, Benatsou, Baya, additional, Coiffier, Benedicte, additional, Laplanche, Agnes, additional, and Lassau, Nathalie, additional

Published
2014
Full Text
View/download PDF

38. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer

Author

Cellier, Patrice, primary, Leduc, Bernard, additional, Martin, Laurent, additional, Vié, Brigitte, additional, Chevelle, Christian, additional, Vendrely, Véronique, additional, Salemkour, Augustin, additional, Carrie, Christian, additional, Calais, Gilles, additional, Burtin, Pascal, additional, Campion, Loïc, additional, Boisdron-Celle, Michèle, additional, Morel, Alain, additional, Berger, Virginie, additional, and Gamelin, Erick, additional

Published
2011
Full Text
View/download PDF

44. The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy

Author

Vuong, Té, primary, Szego, Peter, additional, David, Marc, additional, Evans, Michael, additional, Parent, Josée, additional, Mayrand, Serge, additional, Corns, Robert, additional, Burtin, Pascal, additional, Faria, Sergio, additional, and Devic, Slobodan, additional

Published
2005
Full Text
View/download PDF

48. Video capsule endoscopy (CE) for obscure gastrointestinal bleeding: Feasibility, diagnostic yield and interobserver agreement

Author

Seksik Philippe, Jian Raymond, Landi Bruno, Burtin Pascal, Cellier Christophe, Bloch Francis, Edery Joel, Antoine De Leusse, and Lecomte Thierry

Subjects
Video capsule endoscopy, medicine.medical_specialty, Yield (engineering), Hepatology, business.industry, Gastroenterology, medicine, Radiology, business, Obscure gastrointestinal bleeding
Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results